Understanding over-the-counter medications and prescription devices for eczema: Potential consequences for consumers

Journal of the American Academy of Dermatology

Volumn 63, Issue 6, 2010, Pages 1094-1098

  Green, Julie S ^a   Andersen, Kristen ^a   Wilkin, Jonathan ^b   Siegfried, Elaine ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Wilkin Consulting LLC   (United States)

Author keywords

Active ingredient; Atopic dermatitis; Eczema; Internet; Prescription devices; Products

Indexed keywords

ALLANTOIN; ALUMINUM HYDROXIDE; BICARBONATE; BISMUTH NITRATE; BORIC ACID; CALAMINE; COD LIVER OIL; DECANOIC ACID; DIMETICONE; GLYCEROL; GLYCEROL STEARATE; HEXADECANOL; KAOLIN; LANOLIN; MINERAL OIL; NON PRESCRIPTION DRUG; OCTADECANOL; PALMITIC ACID ISOPROPYL ESTER; PETROLATUM; PROPOLIS; RETINOL; STARCH; SULFUR; TANNIN; THEOBROMA OIL; UNINDEXED DRUG; WHITE PETROLATUM; ZINC ACETATE; ZINC CARBONATE; ZINC OXIDE;

ATOPIC DERMATITIS; BURN; CONSUMER; DATA BASE; ECZEMA; HEALTH CARE ACCESS; INFORMATION PROCESSING; INSECT BITE; INTERNET; NOTE; OAT; POISON IVY; PRESCRIPTION; PRIORITY JOURNAL; SKIN PROTECTION;

EID: 78649346708     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.12.050     Document Type: Editorial

References (7)

1. P.M. Hyman, and R. Carvajal Drugs and other product choices Dermatol Ther 22 2009 216 224
2. Guidance for FDA staff and industry; marketed unapproved drugs-compliance policy guide section 440.100 marketed new drugs without approved NDAs or ANDA. Available from: URL: http://www.fda.gov/CDER/guidance/6911fnl.htm. Accessed May 13, 2009.
3. Federal Food and Drug Administration. 21 CFR food and drugs, 347: final monograph: skin protectant drug products. Available from: URL: http://www.fda.gov/cder/otcmonographs/Skin-Protectant/skin-protectant-FM- 20030604.pdf. Accessed April 16, 2009.
4. Federal Food and Drug Administration. 21 CFR food and drugs, 210: final monograph: skin protectant drug products. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4230b1-03-21%20CFR.pdf. Accessed April 16, 2009.
5. Macintire SJ. Warning letter CHI-5-08 to Joel Heifitz, CEO of Concept Laboratories Inc. August 27, 2008. Available from: URL: http://www.fda.gov/foi/ warning-letters/s6913c.htm. Accessed March 10, 2009.
6. Federal Register/Vol. 63, No. 85/May 4, 1998/notices page 24559. Available from: URL: http://www.fda.gov/ohrms/dockets/98fr/050498g.pdf. Accessed May 13, 2009.
7. R. Hughes, D. Ward, A.M. Tobin, K. Keegan, and B. Kirby The use of alternative medicine in pediatric patients with atopic dermatitis Pediatr Dermatol 24 2007 118 120